BioNTech SE (BNTX)
After hours:
| Previous Close | 132.29 |
| Open | 133.00 |
| Bid | 131.67 x 800 |
| Ask | 133.99 x 1400 |
| Day's Range | 129.22 - 134.26 |
| 52 Week Range | 117.08 - 464.00 |
| Volume | |
| Avg. Volume | 1,388,675 |
| Market Cap | 32.507B |
| Beta (5Y Monthly) | -0.70 |
| PE Ratio (TTM) | 4.25 |
| EPS (TTM) | 31.54 |
| Earnings Date | Nov 09, 2021 |
| Forward Dividend & Yield | 2.11 (1.33%) |
| Ex-Dividend Date | Jun 02, 2022 |
| 1y Target Est | 320.42 |
- GlobeNewswire
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron Geometric mean ratios for Omicron neutralizing antibody response consistent with regulatory requirement of superiorityPreliminary laboratory studies demonstrate both Omicron-adapted candidates neutralize Omicron BA.4 and BA.5
- Reuters
Pfizer/BioNTech say Omicron-based COVID shots improve response vs that variant
Pfizer Inc and BioNTech SE said on Saturday that a booster dose of updated versions of their COVID-19 vaccine, modified specifically to combat the Omicron coronavirus variant, generated a higher immune response against that variant. Advisors to the U.S. Food and Drug Administration are scheduled to meet on Tuesday to discuss whether to update COVID-19 vaccines for the fall. The updated shots are likely to be redesigned to combat the Omicron variant of the coronavirus, experts say.
- Reuters
BioNTtech in conflict with regulator over new COVID vaccine approval - WAS
The launch of German drugmaker BioNTech's vaccine adapted to the Omicron coronavirus variant may be delayed due to a disagreement with the regulator over the approval process, the Welt Am Sonntag (WAS) newspaper reported on Saturday. The regulator should still decide by the end of June whether or not to approve the new vaccine but BioNTech Chief Executive Ugur Sahin does not plan to submit any new clinical trials, WAS reported, citing the Financial Times. The reason for this was that the approval "should go through the same regulatory process as ordinary flu vaccines", which would allow the new COVID-19 vaccine to be delivered in three months, WAS cited Sahin as saying.
